Holen Sie sich die Stockscreener-App
4.84
4.72%
-0.24
Handel nachbörslich:
4.84
Schlusskurs vom Vortag:
$5.08
Offen:
$5.03
24-Stunden-Volumen:
1,454
Relative Volume:
0.04
Marktkapitalisierung:
$165.64M
Einnahmen:
$7.80M
Nettoeinkommen (Verlust:
$-69.02M
KGV:
-2.3998
EPS:
-2.0168
Netto-Cashflow:
$-66.61M
1W Leistung:
-12.00%
1M Leistung:
-24.73%
6M Leistung:
+15.64%
1J Leistung:
+7.80%
1-Tages-Spanne:
$4.5759
$5.03
1-Wochen-Bereich:
$4.5759
$5.53
52-Wochen-Spanne:
$3.32
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Firmenname
Molecular Partners Ag Adr
Sektor
Branche
Telefon
-
Adresse
-
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-08-29 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-04-27 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-07-13 | Eingeleitet | Cowen | Outperform |
| 2021-07-12 | Fortgesetzt | SVB Leerink | Outperform |
Alle ansehen
Molecular Partners Ag Adr Aktie (MOLN) Neueste Nachrichten
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move ... - Yahoo News UK
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit - GlobeNewswire Inc.
Molecular Partners' New Therapy Shows AML Treatment PromiseTipRanks.com - TipRanks
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 - GlobeNewswire Inc.
Molecular Partners Unveils Promising Cancer Therapy - TipRanks
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 - GlobeNewswire Inc.
Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket By Benzinga - Investing.com UK
Molecular Partners Shares Rise on Positive Trial Data for MP0317 - MarketWatch
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 - GlobeNewswire Inc.
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program - GlobeNewswire Inc.
Novartis (NVS) & Molecular Partners Initiate Study for COVID-19 - Yahoo Singapore News
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action - GlobeNewswire Inc.
Life Science Cares Launches in Switzerland - GlobeNewswire Inc.
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting - GlobeNewswire Inc.
Molecular Partners Publishes Invitation to Annual General Meeting 2024 - GlobeNewswire Inc.
Rigel Pharmaceuticals names new Chief Medical Officer By Investing.com - Investing.com
Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero (NASDAQ:MOLN) - Seeking Alpha
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com UK
US stock market gainers for the last week of April 2022 - Nairametrics
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com India
The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOsiShares Biote - Benzinga
Molecular Partners (MLLCF) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Finanzdaten der Molecular Partners Ag Adr-Aktie (MOLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):